

STIC-ILL

check cite

*WIC
QK 180.16*

From: Gambel, Phillip
Sent: Wednesday, November 19, 2003 4:52 PM
To: STIC-ILL
Subject: viral encephalitis

stic

please provide the following reference to

phillip gambel
art unit 1644
308-3997

1644 mailbox 9e12 *Vol. 152(7) 3282-93*

Hamann et al., J. Immunol. 152, 3238 (1994))

WEST Generate Collection | Print

L4: Entry 1 of 54

File: PGPB

Sep 4, 2003

DOCUMENT-IDENTIFIER: US 20030166575 A1

TITLE: Compounds which inhibit leukocyte adhesion mediated by VLA-4

Summary of Invention Paragraph (192):

[0188] The pharmaceutical compositions may be used to treat VLA-4 mediated disease conditions. Such disease conditions include, by way of example, asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes (including acute juvenile onset diabetis), inflammatory bowel disease (including ulcerative colitis and Crohn's disease), multiple sclerosis, rheumatoid arthritis, tissue transplantation, tumor metastasis, meningitis, encephalitis, stroke, and other cerebral traumas, nephritis, retinitis, atopic dermatitis, psoriasis, myocardial ischemia and acute leukocyte-mediated lung injury such as that which occurs in adult respiratory distress syndrome.

Summary of Invention Paragraph (348):

[0331] In addition, certain of the compounds of this invention inhibit, *in vivo*, adhesion of leukocytes to endothelial cells mediated by VLA-4 and, accordingly, can be used in the treatment of diseases mediated by VLA-4. Such diseases include inflammatory diseases in mammalian patients such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes (including acute juvenile onset diabetes), inflammatory bowel disease (including ulcerative colitis and Crohn's disease), multiple sclerosis, rheumatoid arthritis, tissue transplantation, tumor metastasis, meningitis, encephalitis, stroke, and other cerebral traumas, nephritis, retinitis, atopic dermatitis, psoriasis, myocardial ischemia and acute leukocyte-mediated lung injury such as that which occurs in adult respiratory distress syndrome.



[Generate Collection](#)

L4: Entry 9 of 54

File: PGPB

Apr 3, 2003

DOCUMENT-IDENTIFIER: US 20030065185 A1

TITLE: Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4

Summary of Invention Paragraph (154):

[0153] The pharmaceutical compositions may be used to treat VLA-4 mediated disease conditions. Such disease conditions include, by way of example, asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes (including acute juvenile onset diabetes), inflammatory bowel disease (including ulcerative colitis and Crohn's disease), multiple sclerosis, rheumatoid arthritis, tissue transplantation, tumor metastasis, meningitis, encephalitis, stroke, and other cerebral traumas, nephritis, retinitis, atopic dermatitis, psoriasis, myocardial ischemia and acute leukocyte-mediated lung injury such as that which occurs in adult respiratory distress syndrome.

Detail Description Paragraph (158):

[0302] In addition, certain of the compounds of this invention inhibit, *in vivo*, adhesion of leukocytes to endothelial cells mediated by VLA-4 and, accordingly, can be used in the treatment of diseases mediated by VLA4. Such diseases include inflammatory diseases in mammalian patients such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes (including acute juvenile onset diabetes), inflammatory bowel disease (including ulcerative colitis and Crohn's disease), multiple sclerosis, rheumatoid arthritis, tissue transplantation, tumor metastasis, meningitis, encephalitis, stroke, and other cerebral traumas, nephritis, retinitis, atopic dermatitis, psoriasis, myocardial ischemia and acute leukocyte-mediated lung injury such as that which occurs in adult respiratory distress syndrome.



[Generate Collection](#) [Print](#)

L4: Entry 28 of 54

File: USPT

Jun 24, 2003

DOCUMENT-IDENTIFIER: US 6583139 B1

TITLE: Compounds which inhibit leukocyte adhesion mediated by VLA-4

Brief Summary Text (44):

The pharmaceutical compositions may be used to treat VLA-4 mediated disease conditions. Such disease conditions include, by way of example, asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes (including acute juvenile onset diabetes), inflammatory bowel disease (including ulcerative colitis and Crohn's disease), multiple sclerosis, rheumatoid arthritis, tissue transplantation, tumor metastasis, meningitis, encephalitis, stroke, and other cerebral traumas, nephritis, retinitis, atopic dermatitis, psoriasis, myocardial ischemia and acute leukocyte-mediated lung injury such as that which occurs in adult respiratory distress syndrome.

Brief Summary Text (200):

In addition, certain of the compounds of this invention inhibit, *in vivo*, adhesion of leukocytes to endothelial cells mediated by VLA-4 and, accordingly, can be used in the treatment of diseases mediated by VLA-4. Such diseases include inflammatory diseases in mammalian patients such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes (including acute juvenile onset diabetes), inflammatory bowel disease (including ulcerative colitis and Crohn's disease), multiple sclerosis, rheumatoid arthritis, tissue transplantation, tumor metastasis, meningitis, encephalitis, stroke, and other cerebral traumas, nephritis, retinitis, atopic dermatitis, psoriasis, myocardial ischemia and acute leukocyte-mediated lung injury such as that which occurs in adult respiratory distress syndrome.

WEST [Generate Collection](#) [Print](#)

L4: Entry 28 of 54

File: USPT

Jun 24, 2003

US-PAT-NO: 6583139

DOCUMENT-IDENTIFIER: US 6583139 B1

TITLE: Compounds which inhibit leukocyte adhesion mediated by VLA-4

DATE-ISSUED: June 24, 2003

US-CL-CURRENT: 514/227.5; 514/307, 514/365, 544/316, 544/59, 546/147, 548/146, 560/16

APPL-NO: 09/ 688820 [PALM]

DATE FILED: October 17, 2000

PARENT-CASE:

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a Continuation of Ser. No. 09/127,346 filed Jul. 31, 1998, now abandoned, and claims the benefit of U.S. Provisional Application No. 60/104,592, filed Jul. 31, 1997. Each of these applications are incorporated herein by reference in their entirety.